8-K: KORU Medical Achieves Record Revenue, Positive Cash Flow in 2025

KORU Medical Systems announced preliminary unaudited results for Q4 and full year 2025, reporting record revenue and positive operating cash flow.

Summary

• Preliminary fourth quarter 2025 net revenues are expected to be $10.9 million, representing a 23% increase over the prior year period.
• Preliminary full year 2025 net revenues are expected to be $41.1 million, representing a 22% increase over the prior year.
• The company ended the year with a cash balance of $8.9 million.
• Achieved positive cash flow in the fourth quarter and positive cash flow from operations for the full year 2025.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary financial results, including record revenue and positive cash flow, along with strategic progress in international expansion and new market entry (oncology). The tone is highly positive, indicating strong operational performance and future growth potential, despite the preliminary nature of the results.

Positives

• Achieved record net revenues for both the fourth quarter and full year 2025.
• Reported significant revenue growth of 23% in Q4 and 22% for the full year.
• Generated positive cash flow in Q4 2025.
• Achieved positive cash flow from operations for the full year 2025.
• Entering 2026 with solid momentum, driven by continued strength in the core immunoglobulin business and growth in the recurring patient base.
• International expansion strategy is on track.
• Recent 510(k) submission for clearance of the Freedom Infusion System for use with Phesgo represents a key milestone in expanding beyond immunoglobulin into oncology.

Negatives

• The financial results are preliminary and unaudited, subject to adjustment upon completion of review and audit procedures.

Risks

• The preliminary financial results are unaudited and remain subject to change based on the completion of closing and review procedures by the company's independent registered public accountants.
• Actual results may differ materially from forward-looking statements due to potential risks and uncertainties, as detailed under the captions 'Risk Factors' in the Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.

Future Outlook

KORU Medical Systems anticipates entering 2026 with solid momentum, driven by continued strength in its core immunoglobulin business and growth in its recurring patient base. The international expansion strategy is on track, and the recent 510(k) submission for the Freedom Infusion System with Phesgo is a key step in expanding into oncology. The company is positioned for sustainable growth in 2026 and beyond through disciplined execution of its strategy. Final Q4 and full year 2025 results and 2026 guidance are expected in early March 2026.

Management Comments

• "We delivered strong fourth quarter results and enter 2026 with solid momentum, driven by continued strength in our core immunoglobulin business and growth in our recurring patient base."
• "Our international expansion strategy is on track, and our recent 510(k) submission for clearance of the Freedom Infusion System for use with Phesgo represents a key milestone in expanding beyond Ig into oncology."
• "With continued disciplined execution on all aspects of our strategy, we are positioned well for sustainable growth in 2026 and beyond."

Industry Context

KORU Medical Systems operates in the specialized medical technology sector, focusing on large volume subcutaneous infusion solutions. Its expansion beyond immunoglobulin (Ig) into oncology with the 510(k) submission for Phesgo indicates a strategic move to diversify its product applications and tap into broader therapeutic markets, aligning with trends towards home-based care and targeted therapies. The company's focus on patient-centric solutions positions it within a growing segment of healthcare emphasizing convenience and quality of life.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. Therefore, a direct comparison to industry standards based solely on this document is not possible.

Stakeholder Impact

• Shareholders: Positive preliminary financial results, including record revenue and positive cash flow, could lead to increased investor confidence and potential share price appreciation. Strategic expansion into oncology and international markets suggests future growth opportunities.
• Patients: Continued development and commercialization of innovative, patient-centric large volume subcutaneous infusion solutions aim to improve quality of life. Expansion into oncology with Phesgo could offer new treatment options.
• Employees: Strong company performance and growth strategies may indicate job security and potential for expansion.
• Customers (Healthcare Professionals/Biopharmaceutical Companies): Continued product innovation and expansion of the Freedom System, including customization for clinical trials, supports their needs.

Next Steps

• Completion of review and audit procedures by independent registered public accountants for Q4 and full year 2025 financial results.
• Release of final fourth quarter and full year 2025 financial results in early March 2026.
• Release of 2026 guidance in early March 2026.

Key Dates

Recommendation

The preliminary results indicate robust financial health with record revenue growth and a significant shift to positive operating cash flow for the full year, which is a strong indicator of operational efficiency and sustainability. Strategic initiatives like international expansion and the 510(k) submission for oncology applications demonstrate clear pathways for future growth and market diversification. While the results are preliminary, the magnitude of the reported improvements and the strategic milestones achieved suggest a strong underlying business trajectory, making it an attractive investment opportunity.

Keywords

KORU Medical Systems, KRMD, medical technology, subcutaneous infusion, Q4 2025 results, full year 2025 results, revenue growth, cash flow, 510(k) submission, oncology, immunoglobulin, medical devices